The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …

The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis
for immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed
as therapeutics and are a major contributor to neutralizing antibody responses elicited …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein
antigenic sites will inform the development of improved therapeutics. We determined the …

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
but the risk of the virus evolving to escape them remains unclear. Here we map …

Children are strikingly underrepresented in COVID-19 case counts. In the United States,
children represent 22% of the population but only 1.7% of confirmed SARS-CoV-2 cases as of …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

SARS-CoV-2 enters cells using its Spike protein, which is also the main target of
neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated …

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the
identification of immunological correlates of protection in humans. However, to date, studies on …